UK Community Advisory Board (UK-CAB)
Email | |
  • JOIN THE NETWORK

    • UK-CAB 82: Glasgow conference feedback, Gilead Sciences, RIO study update

    28/11/2022 Memory Sachikonye
    Off
    Background reading, Meetings

    Date: 11 November 2022
    Venue: Room MAL 252, Malet Street, Torrington Square, London WC1E 7HX
    Directions from Russell Square tube station

    Programme:

    09.15-09.30 Arrival, expenses, tea and refreshments
    09.45-10.00 Welcome and introductions
    UK-CAB updates
    Company pre-meeting
    10.00-11.00 Glasgow conference feedback:
    –  Conference highlights: Alex Sparrowhawk, UK-CAB
    – Cure research update: Memory Sachikonye, UK-CAB
    11.00-11.15 BREAK
    11.15-12.45 Company meeting: Gilead Sciences
    12.45-14.00 LUNCH
    14.00-14.45 RIO study update – Ming Lee, Imperial College
    14.45-15.30 IAS feedback, Roger Pebody, NAM
    15.30-15.45 BREAK
    15.45-16.30 Members updates; Meeting reflection
    16.30-17.00 Any other business and meeting close

    Presentations from the meeting:

    –  Glasgow Conference highlights: Alex Sparrowhawk
    – Cure research update: Memory Sachikonye
    – RIO Study update: Ming Lee
    – IAS feedback: Roger Pebody

    Background reading:

    Funding

    • Since 2011, i-Base provide admin support to the UK-CAB. Other costs are covered by grants to the UK-CAB. This includes support from drug companies for meetings.
    • Training courses are funded by specific grants, including from the Lottery Fund.
    • From 2008-2011 the CAB was supported by the Monument Trust. This allowed us to employ a part-time administrator.
    • From 2002 to 2008, running costs for the UK-CAB were supported by i-Base. Drug companies funding meeting costs.

    We have always asked HIV drug companies to support the direct costs for UK-CAB meetings.

    This covers travel and accommodation for members coming from out of London. It also covers the cost of catering. This industry funding helps support the CAB as a national project. A list of supporting companies since the UK-CAB was established in 2002 and from the most recent years is included below. 3

    The UK-CAB membership and Steering Group decides the content for all meetings.

    Meetings with a drug company covers their current products and future research. The decision for which companies to invite and the agenda for these meetings is made by the UK-CAB.

    We also ask other researchers to involve the UK-CAB in planning studies and ongoing research. We ask that community involvement in research be included in the budget of grant proposals so that some of the CAB work can be supported in this way by independent research.

    Background reading
    Meetings